ReportsnReports | Product Profiles: HIV - Growing number of FDCs further commoditizes the HIV market
Gilead’s/Bristol-Myers Squibb’s Atripla was the first marketed cross-class fixed dose combination (FDC), an antiretroviral drug class in which drugs from different drug classes are being combined into a single pill to be taken once daily. Today, Atripla is widely accepted as the gold standard in HIV in the US and the five major EU markets (France, Germany, Italy, Spain, and the UK).
See More : HIV market Product Profiles
Browse All: Market Research Reports
Features and benefits
- In-depth discussion of key marketed and pipeline antiretrovirals
- Extensive analysis of clinical trial data and assessment of clinical and commercial attractiveness for pipeline and marketed HIV drugs
- Analysis of life-cycle management and marketing strategies
- Discussion of future strategic opportunities to achieve success in a crowded HIV market
As a result of new FDCs reaching the market, HIV treatment, particularly in first line, will move away from the current "Atripla-for-all-approach" towards a more individualized approach. Tolerability and a drug’s resistance profile will emerge as key differentiation factors between the various available regimens.
The first-to-market cross-class fixed-dose combination (FDC) Atripla is widely accepted as the gold standard in HIV in the US and the five major EU markets (France, Germany, Italy, Spain, and the UK).
Apart from continuing efforts to assess pipeline and marketed drugs in cross-class FDCs and nuc-sparing regimens, there is also an increasing focus on certain subsets of patients, antiretrovirals als pre-exposure prophylaxis (PrEP) and intensification therapies to target residual viral reservoirs.
Table Of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
MARKET DEFINITION AND OVERVIEW
Product overview
New product launches
MARKETED PRODUCT PROFILES
Truvada (tenofovir disoproxil fumarate/emtricitabine; Gilead Sciences)
Drug profile
Development overview
Recent/ongoing key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Atripla (tenofovir disoproxil/emtricitabine/efavirenz; Gilead Sciences/Bristol-Myers Squibb)
Drug profile
Development overview
Recent/ongoing key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Reyataz (atazanavir; Bristol-Myers Squibb)
Drug profile
Development overview
Recent/ongoing key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Prezista (darunavir; Tibotec Pharmaceuticals/Johnson & Johnson)
Drug profile
Development overview
Recent/ongoing key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Isentress (raltegravir; Merck & Co.)
Drug profile
Development overview
Ongoing/recent key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Complera (tenofovir disoproxil fumarate/emtricitabine/rilpivirine; Gilead Sciences/Tibotec Pharmaceuticals/Johnson & Johnson)
Drug profile
Development overview
Ongoing key clinical trials
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for HIV
Edurant (rilpivirine/TMC278; Tibotec Pharmaceuticals/Johnson & Johnson)
Combivir (lamivudine/zidovudine; ViiV Healthcare)
Epzicom/Kivexa (abacavir/lamivudine; ViiV Healthcare)
Sustiva (efavirenz; Bristol-Myers Squibb)
Kaletra (lopinavir/ritonavir; Abbott Laboratories)
Viramune (nevirapine; Boehringer Ingelheim)
Intelence (etravirine; Tibotec/Johnson & Johnson)
Selzentry/Celsentri (maraviroc; ViiV Healthcare)
PIPELINE PRODUCT PROFILES
Quad pill (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat; Gilead Sciences)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
572-Trii (abacavir/lamivudine/S/GSK-1349572; Shionogi & Co./ViiV Healthcare)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Dolutegravir (S/GSK-1349572; Shionogi & Co./ViiV Healthcare)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Cobicistat (GS-9350; Gilead Sciences)
Drug profile
Development overview
Ongoing clinical trials
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for HIV
Elvitegravir (GS-9137; Gilead Sciences)
Lersivirine (UK-453061; ViiV Healthcare)
BMS-663068 (Bristol-Myers Squibb)
GSK-2248761 (ViiV Healthcare)
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX
Contributing experts
Conferences attended
Report methodology
Related Market Research Reports:
- UK Remote Shopping 2012 – the Main Pillar of Multichannel Retailing
- Market and Product Forecasts: Targeted Cancer Therapies – Trend towards personalized medicine will lead to market fragmentation
- Express Benchmarking 2011 – Belgium
- Express Benchmarking 2011 – Finland
- Express Benchmarking 2011 – Germany
- Express Benchmarking 2011 – the Netherlands
- Express Benchmarking 2011 – Italy
- Express Benchmarking 2011- France
- Express Benchmarking 2011 – Austria
- Express Benchmarking 2011 – Czech Republic
ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Blog : Market Research Reports
No comments:
Post a Comment